Pro 2013-003 (Notice of Jianfeng Group Convening the First Extraordinary General Meeting of Shareholders in 2013)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2013-003
Zhejiang Jianfeng Group Co., Ltd.
Notice on Convening the First Extraordinary General Meeting of Shareholders in 2013
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Tips
● Meeting Time: January 22, 2013 (Tuesday) 9:00 a.m.
● Equity Registration Date: January 18, 2013
● Meeting Place: Jianfeng Building
, 88 Wujiang East Road, Jinhua City, Zhejiang Province ● Meeting Method: on-site method
● Whether to provide online voting: No
Basic Information of 1. Meeting
The 8th Meeting of the 8th Board of Directors of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company") was held on December 31, 2012. The meeting decided: at 9:00 a.m. on January 22, 2013 (Tuesday), the company's first extraordinary general meeting of shareholders in 2013 was held on site at Jianfeng Building, No. 88 Wujiang East Road, Jinhua City, Zhejiang Province.
2. Meeting Deliberations
(I) Proposal on the Company's Compliance with the Conditions for Issuing Corporate Bonds;
(II) Proposal on Issuing Corporate Bonds;
1, issue scale
2, allotment arrangement
3 to original shareholders of the company, bond term
4, bond interest rate and determination method
5, issue method
6, issue object
7, guarantee arrangement
8, the purpose of raising funds
9, the listing of issuing bonds
10, the validity period of the resolution
(III) the discussion on requesting the general meeting of shareholders of the company to authorize the board of directors and its authorized persons to handle the matters related to the issuance of corporate bonds;
(IV) a motion to request the Company's general meeting of shareholders to authorize the Board of Directors to take repayment safeguards in the event of an expected failure to pay the principal and interest on the bonds on time or in the event of a failure to pay the principal and interest on the bonds at maturity.
3. Meeting Attendees
. All shareholders of the company and their authorized clients registered with the Shanghai Branch of China Securities Central Depository and Clearing Corporation after the transaction ends on January 18, 2013 (Friday) All clients can attend.
2, Directors, Supervisors and Senior Management of the Company.
4. registration method
1, legal person shareholder holding unit certificate, legal representative power of attorney and attendee ID card registration; Public shareholders register with their shareholder account card and their ID card. Shareholders can pre-register by letter or fax.
2, pre-registration time: January 21, 2013.
3. Place of registration: Room 306, Jianfeng Building, 88 Wujiang East Road, Jinhua City, Zhejiang Province.
Other 5. Matters
1. The meeting is expected to last for half a day. The transportation and accommodation expenses of the participants shall be borne by themselves.
2. Contact address: Room 306, Jianfeng Building, 88 Wujiang East Road, Jinhua City, Zhejiang Province.
3, Postal Code: 321000
4, Tel: 0579-82324699
5, Contact Fax: 0579-82324699
hereby announce
December 31, 2012
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
with Power of Attorney:
Power of Attorney
(newspaper clippings, photocopies and signatures in this format are valid)
hereby fully entrusts (Mr./Ms.) to attend the first extraordinary shareholders' meeting of Zhejiang Jianfeng Group Co., Ltd. in 2013 on my (our) behalf, and in accordance with the following instructions to exercise the right to vote on the meeting motion on behalf of .
The client voted on the following proposals as follows (please draw "√" under the corresponding voting opinions):
Serial Number |
Voting Proposal |
Voting Opinion |
||||
Aside |
Opposing |
Abstaining |
||||
1 |
Proposal on the Company's Compliance with the Conditions for Issuing Corporate Bonds |
|||||
2 |
Proposal on Issuing Corporate Bonds |
|||||
1, Issuance Scale |
||||||
2, Placement Arrangement to Original Shareholders of the Company |
||||||
3, Bond Term |
||||||
4. Bond Interest Rate and Determination Method |
||||||
5, Issuance Method |
||||||
6, Release Object |
||||||
7, Guarantee Arrangement |
||||||
, Use of Raised Funds |
||||||
9, Issued Bonds Listing |
||||||
10, Resolution Validity Period |
||||||
3 |
Proposal on Requiting the General Meeting of Shareholders of the Company to Authorize the Board of Directors and its Authorized Persons to Handle Matters Related to the Issuance of Corporate Bonds |
# | #
### | |||
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page